AR009069A1 - Arilalcanoilpiridazinas, un procedimiento para su preparacion, empleo de las mismas para preparar un medicamento, preparaciones farmaceuticas que lascontienen, y un procedimiento para obtener estas preparaciones farmaceuticas - Google Patents
Arilalcanoilpiridazinas, un procedimiento para su preparacion, empleo de las mismas para preparar un medicamento, preparaciones farmaceuticas que lascontienen, y un procedimiento para obtener estas preparaciones farmaceuticasInfo
- Publication number
- AR009069A1 AR009069A1 ARP970103679A ARP970103679A AR009069A1 AR 009069 A1 AR009069 A1 AR 009069A1 AR P970103679 A ARP970103679 A AR P970103679A AR P970103679 A ARP970103679 A AR P970103679A AR 009069 A1 AR009069 A1 AR 009069A1
- Authority
- AR
- Argentina
- Prior art keywords
- atoms
- pharmaceutical preparations
- procedure
- independently
- hal
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000030507 AIDS Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 1
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Se refiere a los derivados de la arilalcanoilpiridazina, de formula (I), en la que B es A, OA, NH2, NHA, NAA o un heterociclo insaturado con 1 a 4átomos de N, O y/o S, el cual puede no estar sustituido o estar mono, di o trisustituido con Hal, A y/o OA; Q está ausente o es alquileno de 1 a 6 átomosde C; R1, R2 son independientemente -OH, OR5, -SO-R5, -SO2-R5, Hal, -NO2, NH2, -NHR5 o -NR5R6; R1 y R2, juntos, también representan -O-CH2-O-; R3, R4 sonindependientemente H o A; R5, R6 son independientemente A, cicloalquilo de 3 a 7 átomos de C, metilencicloalquilo de 4 a 8 átomos de C o alquenilo de 2 a 8átomos de C; A, A son independientemente alquilo de 1 a 10 átomos de C, eventualmente sustituido con 1 a 5 átomos de F y/o Cl,y Hal es F, Cl, Br o I;y a sus sales aceptables desde el punto de vista fisiologico. Tambié se refiere a un procedimiento para preparar dichos compuestos, a preparacionesfarmacéuticas que los contienen y al empleo de los mismos para eltratamiento de la osteoporosis, los tumores, la aterosclerosis, la artritisreumatoidea, la esclerosis multiple, la diabetes mellitus, los procesos inflamatorios, las alergias, el asma, las enfermedades autoinmunes y los AIDS.Los nuevos compuestos presentan una accion inhibidora de la fosfodiesterasa IV.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19632549A DE19632549A1 (de) | 1996-08-13 | 1996-08-13 | Arylalkanoylpyridazine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR009069A1 true AR009069A1 (es) | 2000-03-08 |
Family
ID=7802479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP970103679A AR009069A1 (es) | 1996-08-13 | 1997-08-13 | Arilalcanoilpiridazinas, un procedimiento para su preparacion, empleo de las mismas para preparar un medicamento, preparaciones farmaceuticas que lascontienen, y un procedimiento para obtener estas preparaciones farmaceuticas |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US6479494B1 (es) |
| EP (1) | EP0922036B1 (es) |
| KR (1) | KR100554876B1 (es) |
| CN (1) | CN1109022C (es) |
| AR (1) | AR009069A1 (es) |
| AT (1) | ATE262512T1 (es) |
| AU (1) | AU725652B2 (es) |
| BR (1) | BR9711066A (es) |
| CA (1) | CA2263417C (es) |
| CZ (1) | CZ291851B6 (es) |
| DE (2) | DE19632549A1 (es) |
| DK (1) | DK0922036T3 (es) |
| ES (1) | ES2214633T3 (es) |
| HU (1) | HUP0001760A3 (es) |
| NO (1) | NO312295B1 (es) |
| PL (1) | PL331557A1 (es) |
| PT (1) | PT922036E (es) |
| RU (1) | RU2201923C2 (es) |
| SI (1) | SI0922036T1 (es) |
| SK (1) | SK282480B6 (es) |
| TW (1) | TW427980B (es) |
| WO (1) | WO1998006704A1 (es) |
| ZA (1) | ZA977206B (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19826841A1 (de) * | 1998-06-16 | 1999-12-23 | Merck Patent Gmbh | Arylalkanoylpyridazine |
| DE19850701A1 (de) | 1998-11-04 | 2000-05-11 | Merck Patent Gmbh | Benzoylpyridazine |
| DE19915364A1 (de) * | 1999-04-06 | 2000-10-12 | Merck Patent Gmbh | Verwendung von Arylalkanoylpyridazinen |
| DE19915365A1 (de) * | 1999-04-06 | 2000-10-12 | Merck Patent Gmbh | Tetrahydropyridazin-Derivate |
| DE19932315A1 (de) * | 1999-07-10 | 2001-01-11 | Merck Patent Gmbh | Benzoylpyridazine |
| SK287231B6 (sk) | 1999-08-21 | 2010-04-07 | Nycomed Gmbh | Liečivo zahŕňajúce PDE inhibítor a agonistu beta2 adrenoreceptora |
| US6794132B2 (en) | 1999-10-02 | 2004-09-21 | Biosite, Inc. | Human antibodies |
| US7135287B1 (en) | 1999-10-02 | 2006-11-14 | Biosite, Inc. | Human antibodies |
| US6680209B1 (en) | 1999-12-06 | 2004-01-20 | Biosite, Incorporated | Human antibodies as diagnostic reagents |
| DE10064997A1 (de) | 2000-12-23 | 2002-06-27 | Merck Patent Gmbh | Benzoylpyridazine |
| EP1368035A1 (en) * | 2001-02-12 | 2003-12-10 | MERCK PATENT GmbH | Use of type 4 phosphodiesterase inhibitors in myocardial diseases |
| HUP0401984A3 (en) * | 2001-10-31 | 2005-06-28 | Merck Patent Gmbh | Use of type 4 phosphodiesterase inhibitors for preparation of pharmaceutical compositions and combination with other active ingredients |
| RU2302412C2 (ru) * | 2001-11-05 | 2007-07-10 | Мерк Патент Гмбх | Гидразоно-малонитрилы |
| DE10224888A1 (de) * | 2002-06-05 | 2003-12-24 | Merck Patent Gmbh | Pyridazinderivate |
| DE10225574A1 (de) * | 2002-06-10 | 2003-12-18 | Merck Patent Gmbh | Aryloxime |
| DE10227269A1 (de) * | 2002-06-19 | 2004-01-08 | Merck Patent Gmbh | Thiazolderivate |
| WO2004087211A2 (en) | 2003-04-01 | 2004-10-14 | Applied Research Systems Ars Holding N.V. | Inhibitors of phosphodiesterases in infertility |
| ES2270715B1 (es) * | 2005-07-29 | 2008-04-01 | Laboratorios Almirall S.A. | Nuevos derivados de pirazina. |
| CA2620333A1 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
| AU2006304787A1 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
| EP2314289A1 (en) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| BRPI0618589B8 (pt) | 2005-11-15 | 2021-05-25 | Otsuka Pharma Co Ltd | composto de oxazol, composição farmacêutica compreendendo o referido composto, processos de fabricação e usos dos mesmos |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| JP2009536667A (ja) | 2006-05-09 | 2009-10-15 | ブレインセルス，インコーポレイティド | ５ｈｔ受容体介在性の神経新生 |
| EP2021000A2 (en) | 2006-05-09 | 2009-02-11 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| MX2009002496A (es) * | 2006-09-08 | 2009-07-10 | Braincells Inc | Combinaciones que contienen un derivado de 4-acilaminopiridina. |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| WO2013106547A1 (en) | 2012-01-10 | 2013-07-18 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5175161A (en) * | 1989-04-06 | 1992-12-29 | Sankyo Company, Limited | Occular hypotensive agents |
| JO1645B1 (en) * | 1989-12-26 | 1991-11-27 | شركة جانسين فارماسوتيكا ان. في | Pyridazine compounds are antibacterial viruses |
| NZ254534A (en) | 1992-07-01 | 1997-12-19 | Ortho Pharma Corp | 1,4,5,6-tetrahydro-pyridazine derivatives, preparation and pharmaceutical compositions thereof |
-
1996
- 1996-08-13 DE DE19632549A patent/DE19632549A1/de not_active Withdrawn
-
1997
- 1997-08-01 PT PT97937540T patent/PT922036E/pt unknown
- 1997-08-01 SK SK168-99A patent/SK282480B6/sk not_active IP Right Cessation
- 1997-08-01 CA CA002263417A patent/CA2263417C/en not_active Expired - Fee Related
- 1997-08-01 DK DK97937540T patent/DK0922036T3/da active
- 1997-08-01 PL PL97331557A patent/PL331557A1/xx unknown
- 1997-08-01 DE DE59711450T patent/DE59711450D1/de not_active Expired - Lifetime
- 1997-08-01 BR BR9711066A patent/BR9711066A/pt not_active IP Right Cessation
- 1997-08-01 EP EP97937540A patent/EP0922036B1/de not_active Expired - Lifetime
- 1997-08-01 ES ES97937540T patent/ES2214633T3/es not_active Expired - Lifetime
- 1997-08-01 CN CN97197181A patent/CN1109022C/zh not_active Expired - Fee Related
- 1997-08-01 CZ CZ1999493A patent/CZ291851B6/cs not_active IP Right Cessation
- 1997-08-01 HU HU0001760A patent/HUP0001760A3/hu unknown
- 1997-08-01 AT AT97937540T patent/ATE262512T1/de not_active IP Right Cessation
- 1997-08-01 SI SI9730631T patent/SI0922036T1/xx unknown
- 1997-08-01 WO PCT/EP1997/004191 patent/WO1998006704A1/de not_active Ceased
- 1997-08-01 RU RU99105211/04A patent/RU2201923C2/ru not_active IP Right Cessation
- 1997-08-01 AU AU40133/97A patent/AU725652B2/en not_active Ceased
- 1997-08-01 KR KR1019997001132A patent/KR100554876B1/ko not_active Expired - Fee Related
- 1997-08-11 TW TW086111479A patent/TW427980B/zh active
- 1997-08-12 ZA ZA9707206A patent/ZA977206B/xx unknown
- 1997-08-13 AR ARP970103679A patent/AR009069A1/es not_active Application Discontinuation
-
1999
- 1999-02-12 NO NO19990676A patent/NO312295B1/no not_active IP Right Cessation
-
2000
- 2000-03-15 US US09/525,455 patent/US6479494B1/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR009069A1 (es) | Arilalcanoilpiridazinas, un procedimiento para su preparacion, empleo de las mismas para preparar un medicamento, preparaciones farmaceuticas que lascontienen, y un procedimiento para obtener estas preparaciones farmaceuticas | |
| LU91145I2 (fr) | FIROCOXIB facultativement sous forme d'un sel pharmaceutiquement acceptable (PREVICOX). | |
| HUP9802630A2 (hu) | Királis metil-fenil-oxazolidinonok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények | |
| SE9203825L (sv) | Dubbelt verkande inhibitorer foer no-syntas och cyklooxygenas, foerfarande foer framstaellning daerav och terapeutiska kompositioner innehaallande desamma | |
| IL123002A0 (en) | 1-Phenyl-2- phenylacetoxy- ethanone derivatives | |
| PT87474A (pt) | Process for the preparation of pharmaceutical compounds which contain ester 1-acetoxi-ethylic of cefuroxime | |
| RU95108329A (ru) | Замещенные производные тиазолидиндиона, способ их получения, фармкомпозиция | |
| AR024060A1 (es) | Nuevos compuestos farmaceuticamente activos | |
| ES2081187T3 (es) | Nuevas naftil-alquil-aminas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen. | |
| TW369535B (en) | A pyrazolopyridine compound and the process for preparing thereof | |
| HUP0100949A2 (hu) | Aril kondenzált azapoliciklusos vegyületek és ezeket tartalmazó gyógyászati készítmények | |
| BG100016A (bg) | Нiv протеазни инхибитори във фармацевтични комбинации за лечение на спин | |
| ATE60579T1 (de) | Pyrrolidinamid-derivate mit antipropylendopeptidase-wirkung, zusammenstellungen, die sie enthalten, verfahren zu ihrer herstellung und heilmittel, die sie enthalten. | |
| AR021068A1 (es) | Benzoilpiridazinas y procedimientos para elaborarlas; preparados farmaceuticos que las contienen y procedimiento para elaborarlos, y utilizacion de dichasbenzoilpiridazinas | |
| ES2141957T3 (es) | Uso de raloxifeno y sus analogos para la produccion de un medicamento para el tratamiento de enfermedades virales. | |
| ES2122637T3 (es) | Derivados de tiazolidina, su preparacion y los medicamentos que les contienen. | |
| AU638979B2 (en) | New benzylcyclanone derivatives, process for preparing them and cosmetic and pharmaceutical compositions containing them | |
| IL82084A0 (en) | 1,4-diazepines,their preparation and pharmaceutical compositions containing them | |
| AR005646A1 (es) | Derivados de la quinolein-2-(1h)-ona, un procedimiento para prepararlos, preparaciones farmaceuticas que los contienen y el empleo de los mismos encalidad de medicamentos | |
| HUP0002754A2 (hu) | (1S,4R)-cisz-4-[2-amino-6-(ciklopropil-amino)-9H-purin-9-il]-2-ciklopentén-1-metanol-hemiszulfát, eljárás előállítására, ezt tartalmazó gyógyszerkészítmény, valamint intermedierek | |
| FI881064A7 (fi) | Menetelmä tulehduksenvastaisten tai analgeettisten -aminoetyylisubstituoitujen fenyyliyhdisteiden valmistamiseksi | |
| ES2037095T3 (es) | Un procedimiento para preparar una composicion farmaceutica. | |
| PT87930A (pt) | Processo para a preparacao de derivados de acido 3-desmetil-4-fluor-mevalonico e de composicoes farmaceuticas que os contem | |
| DE69330601D1 (de) | Serotoninergische ergolin derivate | |
| ES8205224A1 (es) | Un procedimiento para la preparacion de acidos 1-carbadetiapen-2-em-3-carboxilios 6-1-y 2-sustituidos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |